Ferring's fecal transplant on brink of milestone approval

Privately-held Swiss company Ferring Pharmaceuticals and its subsidiary Rebiotix look set to achieve a notable first for the industry.

Their investigational microbiota-based live biotherapeutic RBX2660 - also known as Rebyota - is on the brink of becoming the first microbiome-based therapy to gain a regulatory approval.

Ferring is seeking US Food and Drug Administration (FDA) approval for this fecal microbiota suspension - which is prepared from human stool collected from pre-screened, qualified donors and administered rectally by enema - to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment.